OBJECTIVE: To report our experience with post-chemotherapy nerve-sparing @entity1600 ( @entity1600 ) for @entity2971 ( @entity2971 ). METHODS: Between 1994 and 2008, 92 @entity1 with advanced @entity2971 underwent @entity1600 after multiple treatments with systemic chemotherapy at our institution. A nerve-sparing @entity1600 was carried out in 78 @entity1 (84.8%; median age 32 years). Of them, 19 had a @entity4797 and 59 had a @entity4797 . RESULTS: Lumbar splanchnic nerves controlling ejaculatory function were macroscopically preserved during @entity1600 . Bilateral and unilateral lumbar splanchnic nerves were preserved in 40 @entity1 and 38 @entity1 , respectively. Sixty-five @entity1 could be evaluated for ejaculation. Fifty-four @entity1 (83.1%) achieved antegrade ejaculation with a median postoperative interval of 3 months (range: 1-10 months). Twenty-eight @entity1 (28/30: 93.3%) and 26 @entity1 (26/35: 74.3%) undergoing bilateral and unilateral nerve-sparing @entity1600 had antegrade ejaculation, respectively (P = 0.041). Only two @entity1 (2.6%) had mediastinal and retroperitoneal recurrences during a median follow-up of 42 months (range: 1-138 months), respectively. However, these @entity1 were cured by chemotherapy and surgery. CONCLUSIONS: Post-chemotherapy nerve-sparing @entity1600 preserves ejaculatory function in the majority of @entity1 with advanced @entity2971 without increasing the risk of local recurrence.

Post-chemotherapy nerve-sparing XXXX for @entity2971 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4797 :: ('MESH:D018239', 'Disease') :: ['non-seminoma', 'seminoma'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['RPLND', 'retroperitoneal lymph node dissection'] @entity2971 :: ('MESH:D009373', 'Disease') :: ['advanced germ cell tumor', 'GCT']
@entity1600 :: (MESH:D014388,Disease) :: ['retroperitoneal lymph node dissection']
